The OsteoCool Post-Market Study, “OPuS One,” is a multicenter study and will include up to 250 patients in the United States, Europe, and Canada. The goal of the study is to collect real-world outcomes on effectiveness and safety among a cohort of patients who have been treated with the OsteoCool™ RF ablation system.
EXPANDED COHORT ANALYSIS:
POST PROCEDURE FOLLOW-UP:
Watch OPuS One Global PI, Dr. Sandeep Bagla, and site lead, Dr. Jason Levy, speak with Interventional News at SIR 2019, sharing the preliminary results and takeaways from initial patients included in the study.
PRELIMINARY RESULTS SHOW RAPID PAIN RELIEF
Palliative care for painful bone metastases: Perspectives on OsteoCool bipolar RFA and the OPuS One Study.Read the Interventional News advertorial
International OPuS One study to assess OsteoCool RF ablation for rapid pain palliation in patients with bony metastases.Read the Interventional News advertorial
Pre-ablation worst pain was 8.2 decreasing to 5.6 (n=94) at 3 days, 4.7 (n=89) at 1 week, 3.9 (n=64) at 1 month, 3.7 (n=46) at 3 months, and 3.5 (n=22) at 6 months. P<0.0001 all visits.